FOLFOX and FLOX Regimens for the Adjuvant Treatment of Resected Stage II and III Colon Cancer

被引：65

作者：

Sharif, Saima ^{[1
,2
]}

O'Connell, Michael J. ^{[1
]}

Yothers, Greg ^{[1
,3
]}

Lopa, Samia ^{[1
,3
]}

Wolmark, Norman ^{[1
,2
]}

机构：

[1] Univ Pittsburgh, Natl Surg Adjuvant Breast & Bowel Project Operat, Pittsburgh, PA USA

[2] Univ Pittsburgh, Allegheny Gen Hosp, Pittsburgh, PA USA

[3] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA

来源：

CANCER INVESTIGATION | 2008年 / 26卷 / 09期

关键词：

Colon cancer; adjuvant chemotherapy; oxaliplatin; adjuvant therapy;

D O I：

10.1080/07357900802132550

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The MOSAIC trial showed that the use of adjuvant oxaliplatin and an infusional regimen of 5-FU/LV in the treatment of stage II/III colon cancer improved disease-free survival (DFS). The NSABP's C-07 trial evaluated the addition of oxaliplatin to a weekly Roswell Park regimen of bolus 5-FU/LV and found a similar improvement in DFS. The benefit of oxaliplatin appears to be independent of the 5-FU/LV regimen used. This paper reviews the efficacy and toxicities of these two regimens and is meant to serve as a guide for clinical practice.

引用

页码：956 / 963

页数：8

共 18 条

[1] Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].

Andre, T ;

Boni, C ;

Mounedji-Boudiaf, L ;

Navarro, M ;

Tabernero, J ;

Hickish, T ;

Topham, C ;

Zaninelli, M ;

Clingan, P ;

Bridgewater, J ;

Tabah-Fisch, I ;

de Gramont, A .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351

[2]

CASSIDY J, 2007, P AM SOC CLIN ONCOL, V25

[3] Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].

Cunningham, D ;

Humblet, Y ;

Siena, S ;

Khayat, D ;

Bleiberg, H ;

Santoro, A ;

Bets, D ;

Mueser, M ;

Harstrick, A ;

Verslype, C ;

Chau, I ;

Van Cutsem, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345

[4]

de Gramont A, 2007, J CLIN ONCOL, V25, DOI 10.1200/JCO.2006.10.4380

[5] Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J].

de Gramont, A ;

Figer, A ;

Seymour, M ;

Homerin, M ;

Hmissi, A ;

Cassidy, J ;

Boni, C ;

Cortes-Funes, H ;

Cervantes, A ;

Freyer, G ;

Papamichael, D ;

Le Bail, N ;

Louvet, C ;

Hendler, D ;

de Braud, F ;

Wilson, C ;

Morvan, F ;

Bonetti, A .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :2938-2947

[6] Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study [J].

deGramont, A ;

Basset, JF ;

Milan, C ;

Rougier, P ;

Bouche, O ;

Etienne, PL ;

Morvan, F ;

Louvet, C ;

Guillot, C ;

Francois, E ;

Bedenne, L .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) :808-815

[7]

DEGRAMONT A, 2005, P AN M AM SOC CLIN, V23, P16

[8] Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial [J].

Douillard, JY ;

Cunningham, D ;

Roth, AD ;

Navarro, M ;

James, RD ;

Karasek, P ;

Jandik, P ;

Iveson, T ;

Carmichael, J ;

Alakl, M ;

Gruia, G ;

Awad, L ;

Rougier, P .

LANCET, 2000, 355 (9209) :1041-1047

[9] A Randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer [J].

Goldberg, RM ;

Sargent, DJ ;

Morton, RF ;

Fuchs, CS ;

Ramanathan, RK ;

Williamson, SK ;

Findlay, BP ;

Pitot, HC ;

Alberts, SR .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) :23-30

[10] Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J].

Hurwitz, H ;

Fehrenbacher, L ;

Novotny, W ;

Cartwright, T ;

Hainsworth, J ;

Heim, W ;

Berlin, J ;

Baron, A ;

Griffing, S ;

Holmgren, E ;

Ferrara, N ;

Fyfe, G ;

Rogers, B ;

Ross, R ;

Kabbinavar, F .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2335-2342

← 1 2 →